CovidChloroV1, Main, Corpus, bibRecord, 000764

SUBACUTE THYROIDITIS IN A PATIENT WITH CORONAVIRUS DISEASE 2019.

Identifieur interne : 000764 ( Main/Corpus ); précédent : 000763; suivant : 000765

SUBACUTE THYROIDITIS IN A PATIENT WITH CORONAVIRUS DISEASE 2019.

Auteurs : Mari Des J. San Juan ; Mary Queen V. Florencio ; Mark Henry Joven

Source :

AACE clinical case reports [ 2376-0605 ]

RBID : pubmed:33244504

Abstract

Objective

Subacute thyroiditis (SAT) is an inflammatory disorder of the thyroid gland that causes destructive thyrotoxicosis and is attributed to a viral or post-viral response. SARS-CoV-2 is a novel coronavirus that caused a global pandemic in 2020. We present a case that suggests that there may be a relationship between SAT and corona-virus disease 2019 (COVID-19).

Methods

We describe the clinical findings, thyroid function tests, and neck ultrasound of a patient presenting with anterior neck pain.

Results

A 47-year-old, Filipino female presented with anterior neck pain associated with neck tenderness and goiter. She did not have fever or respiratory symptoms but had right lower lobe pneumonia on chest radiograph. Thyroid function tests were consistent with subclinical hyperthyroidism with thyroid-stimulating hormone of 0.05 μIU/mL (reference range is 0.47 to 4.68 μIU/mL), free thyroxine of 1.68 pg/mL (reference range is 0.78 to 2.19 pg/mL), and total triiodothyronine of 1.4 ng/mL (reference range is 0.97 to 1.69 ng/mL). Anti-thyroid peroxidase, anti-thyroglobulin, and thyroid-stimulating hormone receptor antibodies were negative. Neck ultrasound showed heterogenous thyroid tissues with normal vascularity. Reverse transcription-polymerase chain reaction for SARS-CoV-2 using nasopharyngeal and oropharyngeal swabs were positive. The patient was diagnosed as having SAT and was treated with mefenamic acid, which was later switched to celecoxib. Ceftriaxone and hydroxychloroquine were started for COVID-19 pneumonia. Complete resolution of symptoms and primary hypothyroidism occurred after 2 months.

Conclusion

SAT may be a presenting symptom or a sequela of COVID-19. Histopathology studies and definitive documentation of the virus in thyroid tissues may be required to confirm the relationship between SAT and COVID-19.

DOI: 10.4158/ACCR-2020-0524
PubMed: 33244504
PubMed Central: PMC7685420

Links to Exploration step

pubmed:33244504

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">SUBACUTE THYROIDITIS IN A PATIENT WITH CORONAVIRUS DISEASE 2019.</title>
<author><name sortKey="San Juan, Mari Des J" sort="San Juan, Mari Des J" uniqKey="San Juan M" first="Mari Des J" last="San Juan">Mari Des J. San Juan</name>
</author>
<author><name sortKey="Florencio, Mary Queen V" sort="Florencio, Mary Queen V" uniqKey="Florencio M" first="Mary Queen V" last="Florencio">Mary Queen V. Florencio</name>
</author>
<author><name sortKey="Joven, Mark Henry" sort="Joven, Mark Henry" uniqKey="Joven M" first="Mark Henry" last="Joven">Mark Henry Joven</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020 Nov-Dec</date>
<idno type="RBID">pubmed:33244504</idno>
<idno type="pmid">33244504</idno>
<idno type="doi">10.4158/ACCR-2020-0524</idno>
<idno type="pmc">PMC7685420</idno>
<idno type="wicri:Area/Main/Corpus">000764</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000764</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">SUBACUTE THYROIDITIS IN A PATIENT WITH CORONAVIRUS DISEASE 2019.</title>
<author><name sortKey="San Juan, Mari Des J" sort="San Juan, Mari Des J" uniqKey="San Juan M" first="Mari Des J" last="San Juan">Mari Des J. San Juan</name>
</author>
<author><name sortKey="Florencio, Mary Queen V" sort="Florencio, Mary Queen V" uniqKey="Florencio M" first="Mary Queen V" last="Florencio">Mary Queen V. Florencio</name>
</author>
<author><name sortKey="Joven, Mark Henry" sort="Joven, Mark Henry" uniqKey="Joven M" first="Mark Henry" last="Joven">Mark Henry Joven</name>
</author>
</analytic>
<series><title level="j">AACE clinical case reports</title>
<idno type="eISSN">2376-0605</idno>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>Objective</b>
</p>
<p>Subacute thyroiditis (SAT) is an inflammatory disorder of the thyroid gland that causes destructive thyrotoxicosis and is attributed to a viral or post-viral response. SARS-CoV-2 is a novel coronavirus that caused a global pandemic in 2020. We present a case that suggests that there may be a relationship between SAT and corona-virus disease 2019 (COVID-19).</p>
</div>
<div type="abstract" xml:lang="en"><p><b>Methods</b>
</p>
<p>We describe the clinical findings, thyroid function tests, and neck ultrasound of a patient presenting with anterior neck pain.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>Results</b>
</p>
<p>A 47-year-old, Filipino female presented with anterior neck pain associated with neck tenderness and goiter. She did not have fever or respiratory symptoms but had right lower lobe pneumonia on chest radiograph. Thyroid function tests were consistent with subclinical hyperthyroidism with thyroid-stimulating hormone of 0.05 μIU/mL (reference range is 0.47 to 4.68 μIU/mL), free thyroxine of 1.68 pg/mL (reference range is 0.78 to 2.19 pg/mL), and total triiodothyronine of 1.4 ng/mL (reference range is 0.97 to 1.69 ng/mL). Anti-thyroid peroxidase, anti-thyroglobulin, and thyroid-stimulating hormone receptor antibodies were negative. Neck ultrasound showed heterogenous thyroid tissues with normal vascularity. Reverse transcription-polymerase chain reaction for SARS-CoV-2 using nasopharyngeal and oropharyngeal swabs were positive. The patient was diagnosed as having SAT and was treated with mefenamic acid, which was later switched to celecoxib. Ceftriaxone and hydroxychloroquine were started for COVID-19 pneumonia. Complete resolution of symptoms and primary hypothyroidism occurred after 2 months.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>Conclusion</b>
</p>
<p>SAT may be a presenting symptom or a sequela of COVID-19. Histopathology studies and definitive documentation of the virus in thyroid tissues may be required to confirm the relationship between SAT and COVID-19.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33244504</PMID>
<DateRevised><Year>2020</Year>
<Month>11</Month>
<Day>28</Day>
</DateRevised>
<Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2376-0605</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>6</Volume>
<Issue>6</Issue>
<PubDate><MedlineDate>2020 Nov-Dec</MedlineDate>
</PubDate>
</JournalIssue>
<Title>AACE clinical case reports</Title>
<ISOAbbreviation>AACE Clin Case Rep</ISOAbbreviation>
</Journal>
<ArticleTitle>SUBACUTE THYROIDITIS IN A PATIENT WITH CORONAVIRUS DISEASE 2019.</ArticleTitle>
<Pagination><MedlinePgn>e361-e364</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4158/ACCR-2020-0524</ELocationID>
<Abstract><AbstractText Label="Objective" NlmCategory="UNASSIGNED">Subacute thyroiditis (SAT) is an inflammatory disorder of the thyroid gland that causes destructive thyrotoxicosis and is attributed to a viral or post-viral response. SARS-CoV-2 is a novel coronavirus that caused a global pandemic in 2020. We present a case that suggests that there may be a relationship between SAT and corona-virus disease 2019 (COVID-19).</AbstractText>
<AbstractText Label="Methods" NlmCategory="UNASSIGNED">We describe the clinical findings, thyroid function tests, and neck ultrasound of a patient presenting with anterior neck pain.</AbstractText>
<AbstractText Label="Results" NlmCategory="UNASSIGNED">A 47-year-old, Filipino female presented with anterior neck pain associated with neck tenderness and goiter. She did not have fever or respiratory symptoms but had right lower lobe pneumonia on chest radiograph. Thyroid function tests were consistent with subclinical hyperthyroidism with thyroid-stimulating hormone of 0.05 μIU/mL (reference range is 0.47 to 4.68 μIU/mL), free thyroxine of 1.68 pg/mL (reference range is 0.78 to 2.19 pg/mL), and total triiodothyronine of 1.4 ng/mL (reference range is 0.97 to 1.69 ng/mL). Anti-thyroid peroxidase, anti-thyroglobulin, and thyroid-stimulating hormone receptor antibodies were negative. Neck ultrasound showed heterogenous thyroid tissues with normal vascularity. Reverse transcription-polymerase chain reaction for SARS-CoV-2 using nasopharyngeal and oropharyngeal swabs were positive. The patient was diagnosed as having SAT and was treated with mefenamic acid, which was later switched to celecoxib. Ceftriaxone and hydroxychloroquine were started for COVID-19 pneumonia. Complete resolution of symptoms and primary hypothyroidism occurred after 2 months.</AbstractText>
<AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">SAT may be a presenting symptom or a sequela of COVID-19. Histopathology studies and definitive documentation of the virus in thyroid tissues may be required to confirm the relationship between SAT and COVID-19.</AbstractText>
<CopyrightInformation>Copyright © 2020 AACE.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>San Juan</LastName>
<ForeName>Mari Des J</ForeName>
<Initials>MDJ</Initials>
</Author>
<Author ValidYN="Y"><LastName>Florencio</LastName>
<ForeName>Mary Queen V</ForeName>
<Initials>MQV</Initials>
</Author>
<Author ValidYN="Y"><LastName>Joven</LastName>
<ForeName>Mark Henry</ForeName>
<Initials>MH</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>11</Month>
<Day>23</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>AACE Clin Case Rep</MedlineTA>
<NlmUniqueID>101670593</NlmUniqueID>
<ISSNLinking>2376-0605</ISSNLinking>
</MedlineJournalInfo>
<CoiStatement>DISCLOSURE The authors have no multiplicity of interest to disclose.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>07</Month>
<Day>28</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>09</Month>
<Day>21</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>11</Month>
<Day>27</Day>
<Hour>5</Hour>
<Minute>46</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>11</Month>
<Day>28</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>11</Month>
<Day>28</Day>
<Hour>6</Hour>
<Minute>1</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">33244504</ArticleId>
<ArticleId IdType="doi">10.4158/ACCR-2020-0524</ArticleId>
<ArticleId IdType="pmc">PMC7685420</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Adv Res. 2020 Mar 16;24:91-98</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32257431</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Autoimmun. 2020 May;109:102433</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32113704</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virol J. 2009 Jan 12;6:5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19138419</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Endocrinol Metab. 2003 May;88(5):2100-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12727961</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 1957 May 25;272(6978):1062-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">13429875</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Tissue Antigens. 1984 Jul;24(1):58-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6333089</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>An Med Interna. 2000 Oct;17(10):546-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11109652</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Heart Lung. 2013 Jan-Feb;42(1):77-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22819125</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Presse Med. 2007 May;36(5 Pt 1):808-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17383147</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Endocrine. 2010 Jun;37(3):440-1</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20960165</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med Clin North Am. 2012 Mar;96(2):223-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22443972</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Med. 2009 Apr;122(4):e5-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19332218</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Thyroid. 2004 Jul;14(7):544-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15307945</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Clin Microbiol Infect Dis. 2020 Jun;39(6):1011-1019</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32291542</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2020 May 28;181(5):1016-1035.e19</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32413319</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Endocrinol Metab. 2020 Jul 1;105(7):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32436948</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Head Neck Pathol. 2019 Jun;13(2):231-234</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29427032</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000764 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000764 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:33244504
   |texte=   SUBACUTE THYROIDITIS IN A PATIENT WITH CORONAVIRUS DISEASE 2019.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i   -Sk "pubmed:33244504" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

SUBACUTE THYROIDITIS IN A PATIENT WITH CORONAVIRUS DISEASE 2019.

SUBACUTE THYROIDITIS IN A PATIENT WITH CORONAVIRUS DISEASE 2019.

Source :

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki